Navigation Links
Major clinical study rejects cancer safety fears of most common heartburn treatment
Date:9/9/2009

Fears about the cancer causing effects of the second most prescribed group of drugs in the Western world have been put to rest, following the largest ever study into their use.

'Proton pump inhibitors' (PPI) are the most commonly used treatment for chronic acid reflux, or 'heartburn', a painful burning sensation in the chest, neck and throat which is experienced by almost a third of people in developed countries.

Regular and prolonged heartburn is known to cause 'benign oesophagitis', a reversible inflammation of the gullet. However if left untreated a condition called Barrett's Oesophagus (BE) occurs in around 10 per cent of sufferers, which can in turn develop into a potentially fatal cancer called oesophageal adenocarcinoma.

BE is twice as common in the UK as it is in the USA, and oesophageal cancer rates in the UK are the highest in the world; up to four times more common than in other European countries.

Despite their excellent safety record, it was unclear if long-term use of PPIs to reduce the discomfort of heartburn could increase the risk of developing either BE or the spread of the associated cancer.

New research carried out at Queen Mary, University of London and Leicester Royal Infirmary, has given the most conclusive evidence yet that this is not the case. The work is published in the peer reviewed journal Gut.

Professor Janusz Jankowski, who co-authored the study, said: "This is one of the most detailed studies investigating both the laboratory and clinical side of proton pump inhibitor drugs. As a consequence we are now better able to inform patients of the good benefit/risk ratio of this commonly prescribed therapy."

Tests carried out during the two-year study looked at tissue sampled from the oesophagus lining of ninety volunteers, each of whom were given PPI drugs at either a high or low dosage. Researchers found there was no difference in the rate at which BE developed, neither was there a change in the number of precancerous cells in either group.

While there had also been fears about how the treatments might affect people already suffering from BE, the study also showed that there was no evidence that this led to any worsening of the condition or any extra incidences of cancer.

BE is marked by changes in the cells of the oesophagus lining (squamous epithelium) that makes them more like the cells of the intestines (columnar epithelium). As well as increasing the risk of oesophageal cancer, the condition narrows the oesophagus and patients can experience pain whilst swallowing. The chance of cancer developing is proportional to the length of BE.

PPIs work by blocking the action of gastrin, a hormone that controls acid levels in the stomach, and is known to increase the normal movement of cells in the gastro-intestinal tract. Since PPI therapy increases the levels of gastrin in the body, it had been thought this could cause expansion of BE affected tissue, but this was not found to be the case: the scientists observed neither expansion or contraction of the abnormal tissue. This is concordant with current UK practice, where PPI therapy is currently only licensed to treat heartburn and 'oesophagitis' but not BE.


'/>"/>

Contact: Simon Levey
s.levey@qmul.ac.uk
44-207-882-5404
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain
2. NIH awards major grant to Chicago-based consortium to create center for AIDS research
3. Cancer Community Alarmed at CMS Policy Lumping Life-Saving Cancer Therapy With Diagnostic Testing For Major Funding Cuts
4. Major League Baseball Pitchers John Smoltz and Derek Lowe Help Raise Awareness Throughout Prostate Cancer Awareness Month
5. In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company
6. In Final Hour Prior to Litigation, Angel MedFlights Air Ambulance Team Overturns Decision by Major Insurance Company
7. Red Cross Survey Finds Overwhelming Majority of Public Taking Steps against H1N1 Flu Virus
8. Gene variation is major genetic determinant of psoriasis
9. Viral Genetics Completes Second Major Debt Conversion
10. IU national survey finds majority of Americans believe myths about health care reform
11. Prostate Net Announces: Major Medical Education Initiative for Patients, Caregivers and Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... bioelectronic medicine device WellnessPro Plus for consumers and healthcare professionals to manage ... platform by expanding the treatment modalities available in a single device. The ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers to ... , “Fred Rides a Train” is the creation of published author, Janet Morrison, ... teen years in Michigan. The "Fred, the Dog" series is her first attempt at ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Hacking into my medical ... described him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in the ... by Wyston Books, Inc. These novels narrate the lives of a poor ...
(Date:12/6/2016)... ... , ... According to a November 1 article published on Bustle, ... not drinking enough water, which can cause bad breath (known medically as halitosis). Dr. ... hygiene not only helps reduce the possibility of bad breath, but it can provide ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the Maine Women’s Magazine inaugural Maine Women’s Expo. Hundreds of women gathered to ... amazing local resource. The expo’s beneficiary this year was Crossroads, a fully-accredited ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... LONDON , Dec. 6, 2016 /PRNewswire/ ... Review, H2 2016 Summary Global ... pipeline guide Homozygous Familial Hypercholesterolemia (HoFH) – ... of the Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic ... is a genetic disorder which is caused ...
(Date:12/6/2016)... , Dec. 6, 2016   AlloSource , ... cellular, bone, skin and soft-tissue allografts for use ... Business Process Manager, for being named to the ... National Quality Award by the Commerce Department,s National ... organization,s commitment to process excellence. The Baldrige Award ...
(Date:12/6/2016)... , Dec. 6, 2016 Two new ... personnel in a simulated mass casualty event Tuesday at ... . The technology debuted before an audience including ... and representatives from Homeland Security, Federal Law Enforcement Agencies, ... Project, known as HiRO (Health Integrated Rescue Operations), was ...
Breaking Medicine Technology: